Introduction {#s1}
============

The incidence of malignant melanoma has risen steadily during the last few decades, particularly in the Caucasian population (Siegel et al., [@B130]). According to GLOBOCAN (Global Cancer Observatory[^1^](#fn0001){ref-type="fn"}), more than 287,723 new cases of melanoma of the skin (1.6% of all cancers) occurred worldwide in 2018, and \~60,712 deaths were reported. In Italy, a total of 13,000 cases were diagnosed in 2018, and a similar number was estimated for 2019 (NUMERI DEL CANCRO AIOM AIRTUM, January 2020[^2^](#fn0002){ref-type="fn"}).

The etiology of melanoma is mostly related to mutagenic damages caused by the UVs with the involvement of many tumor suppressor genes and/or oncogenes (Hodis et al., [@B61]; Krauthammer et al., [@B77]; Akbani et al., [@B1]; Hayward et al., [@B59]). Indeed, cutaneous melanoma is characterized by a high prevalence of somatic mutations, both in the primary tumor and in the metastatic lesions, with a mean mutational burden over 20 mutations per megabase (Alexandrov et al., [@B2]; Akbani et al., [@B1]), one of the highest Tumor Mutation Burden (TMB) measurements among all solid tumors (Alexandrov et al., [@B2]; Zhang et al., [@B159]). TMB is correlated with clinical response to cytotoxic T lymphocyte--associated antigen−4 blockade in advanced melanoma and with anti--programmed cell death protein−1 (PD-1) and/or PD-L1 blockade in melanoma (Snyder et al., [@B131]; Van Allen et al., [@B150]; Hugo et al., [@B63]; Johnson et al., [@B70]; Goodman et al., [@B54]; Cristescu et al., [@B27]). BRAF is a key element of the MAPK pathway, and it is physiologically activated by the binding between extracellular signals and their membrane receptor, typically a Tyrosine Kinases Receptor (TKR) (Lito et al., [@B83]). Activated BRAF kinase activates MEK, which, in turn, activates ERK, regulating cell proliferation and survival. An activating mutation in *BRAF*, with a constitutive activation of the kinase, is found in about 50% of cutaneous melanomas, mostly the *BRAF* V600E (Tate et al., [@B141]). On this basis, targeted therapies for the treatment of *BRAF* mutated, advanced, or metastatic melanoma were introduced in treatment protocols. First, BRAF inhibitors were approved as single agents (Queirolo and Spagnolo, [@B114]). Subsequently, the combination of BRAF inhibitors plus MEK inhibitors seemed to further improve the outcome in terms of Overall Survival (OS) among treated patients and combination therapy became the standard of treatment for BRAF mutant melanoma. Targeted therapies radically improved efficacy and survival outcomes among these patients, with a median OS of 25.9 months (Robert et al., [@B119]), whereas, historically, median survival with chemotherapy and bio-chemotherapy was only about 6 months (Korn et al., [@B76]).

More recently, between 2018 and December 2019, FDA and EMA released the approval for prescribing BRAF and MEK inhibitors in high-risk resected (stage III) melanoma patients (Spagnolo et al., [@B133]). Adjuvant treatment with combined BRAF and MEK inhibitors achieved a 53% decrease in the risk of relapse compared with placebo (Long et al., [@B84]).

The dramatic improvements in the outcomes in *BRAF*-mutated melanoma patients receiving BRAF and MEK inhibitors highlights the need for molecular assessment, which has become a necessary step to identify patients who are best suitable for targeted therapies or immunotherapies. However, despite several trials and studies having proven the efficacy of immuno checkpoint inhibitors (Moser et al., [@B100]; Pavlick et al., [@B106]) and targeted therapies in OS, no direct comparison has been performed so far, and the choice between the two therapeutic approaches in BRAF mutated melanoma is still debated. In this review, we will report the most commonly used *BRAF* diagnostic strategies for melanoma and the emerging techniques in the liquid biopsy field.

Molecular Background {#s2}
====================

Over the past few decades, growing efforts have shown that tumors often show recurrent oncogenic mutations, amplifications, and rearrangements in the genes that drive cell to proliferation and survival. These alterations can occur in different genes considered "drivers" and can be mutually exclusive within the same tumor, such as *BRAF* and *NRAS* gene mutations. However, some studies showed *BRAF* and *NRAS* mutations in the same tumor samples, suggesting that these mutations are not mutually exclusive in melanoma but exhibit intra-tumoral heterogeneity (Sensi et al., [@B128]; Jovanovic et al., [@B72]).

The Cancer Genome Atlas (TCGA) database and other key sequencing studies has provided a comprehensive survey of the genetic landscape of cutaneous melanomas. Data published with TCGA Network, after the whole exome sequence analysis of 333 primary and/or metastatic melanoma patients, found that cutaneous melanomas could be classified into four genomic subgroups: mutant *BRAF*, mutant *NRAS*, mutant *NF1*, and triple-wild type (Berger et al., [@B8]; Furney et al., [@B48]; Akbani et al., [@B1]; Johansson et al., [@B69]; Hayward et al., [@B59]; Hintzsche et al., [@B60]; Lyu et al., [@B90]; Palmieri et al., [@B103]; Wilmott et al., [@B154]; Zhou et al., [@B160]). Critical signaling pathways in cutaneous melanoma are the RAS-RAF-MEK-ERK, PI3K/PTEN, and c-Kit pathways. The MAPK pathway physiologically plays a key role in the control of cell proliferation and cell differentiation (Dhillon et al., [@B36]). This pathway consists of several molecules that interact to each other in an on/off mechanism mediated by phosphorylation and dephosphorylation cycles. This signaling cascade induces the production of intracellular signals aimed to promote cellular growth, differentiation, and division ([Figure 1](#F1){ref-type="fig"}). The transmembrane TKR/growth factor receptors (GFR) is the first molecule involved. The binding of this receptor to a growth factor results in the activation of RAS. RAS belongs to the GTPase family and acts as an on/off switch by activating or deactivating the entire downstream path (Gaestel, [@B49]). It activates the subsequent element in the cascade: RAF (a serine/threonine kinase with three isoforms---ARAF, BRAF, and CRAF---each of them with distinct characteristics in tissue distribution, kinase activity, and regulation) (Kwong and Chin, [@B78]; Matallanas et al., [@B95]). In turn, RAF phosphorylates and activates MEK (MEK1/2) and this process is repeated in successive phosphorylation steps ending with ERK activation. ERK ultimately acts by regulating the expression of a series of genes involved in proliferation, differentiation and survival. At the same time, activated ERK inhibits the MAPK pathway, acting as a negative feedback. Mutations of RAS, RAF, and MEK were described in a large number of tumors: for example, RAS mutations have been found in about 1/3 of all human tumors and in 15--20% of melanomas, and *BRAF* is mutated in 8% of human tumors and in about 40--50% of melanomas. Moreover, a 15% of melanomas shows mutations of *NF1* with loss of function. All of these genetic changes result in alterations of MAPK signaling functioning with uncontrolled cell proliferation (Wan et al., [@B153]).

![Schematic view of the MAPK and PI3K pathways.](fmolb-07-00113-g0001){#F1}

The identification of *BRAF* mutations is crucial for personalized treatment of melanoma, being an important tool for diagnosis, treatment, predictor of patient outcomes, and may have an impact on prognosis (Barbour et al., [@B7]). Patients harboring activating mutations in *BRAF, NRAS*, and *KIT* genes could benefit of target treatment options. Despite this good purpose, to date, only *BRAF* mutations have FDA approved therapies in advanced cutaneous melanoma, whereas *KIT* mutations have the tyrosine kinase inhibitors Imatinib as off-label prescription. Based on recent ESMO Clinical Practice Guidelines, *BRAF* mutation testing is mandatory in patients with resectable or unresectable stage III or stage IV melanoma and is highly recommended in high-risk resected disease stage IIC patients (Michielin et al., [@B99]). In the metastatic setting, it is recommended to perform molecular analyses in metastatic sample, if available, because it represents the most recent lesion and it is often composed by a large majority of neoplastic cells. When a metastatic tissue sample is not available, the analyses may be performed on samples obtained from lymph node metastases or primary tumor since a high concordance of the *BRAF* status between primary melanomas and their metastatic lesions has been demonstrated (Colombino et al., [@B24]; Casula et al., [@B20]; Valachis and Ullenhag, [@B147]; Cormican et al., [@B26]; Pellegrini et al., [@B108]). Additionally, the NCCN clinical practice guidelines recommend *BRAF* mutation testing in patients with resectable and unresectable or metastatic melanoma to guide treatment decisions (NCCN Clinical Practice Guidelines in Oncology[^3^](#fn0003){ref-type="fn"})?

Mutational analysis is normally performed on Formalin-Fixed Paraffin-Embedded (FFPE) tissues, after removal of paraffin and DNA extraction with standardized protocols. Prior to molecular analysis, the sample must undergo enrichment, as the proportion of cancer cells should not be lower than 50% of the total. In case of melanomas arising on pre-existing nevi, particular care should be taken during the enrichment process to make sure that only melanoma cells are isolated from the tissue sample, as also melanocytic nevi can carry *BRAF* mutations. *BRAF* mutations occur quite often in melanomas, conferring to this kinase the ability to independently activate MEK, inducing its constitutive activation (Johnson and Sosman, [@B71]). However, mutations in *BRAF* are early and not sufficient to induce melanoma: there is a high frequency of these mutations in benign nevi (including congenital, intra-dermal, and dysplastic) (Pollock et al., [@B112]; Tschandl et al., [@B144]), and it seems that additional genetic events are necessary.

The discovery of *BRAF* mutation and its meaning occurred in 2002 and to date, about 300 *BRAF* mutations have been characterized, most in codon 600: this discovery paved the way for the development of new molecular-target drugs (Flaherty et al., [@B43]). Indeed, 37 to 60% of melanomas, typically those related to intermittent sun exposure damage, show a somatic mutation in *BRAF* (Curtin et al., [@B29]). Most *BRAF* mutations are missense variations that determine aminoacid substitution at valine 600. From 70, up to 88% of *BRAF* mutations are represented by V600E (valine to glutamic acid), but V600K (valine to lysine substitution) or V600D (valine to aspartic acid) and V600R (valine to arginine) are found in 5--12% and ≤ 5% of melanomas, respectively. (Rubinstein et al., [@B121]; Long et al., [@B85]; Lovly et al., [@B89]; Menzies et al., [@B98]). Recently, Yao et al. has further categorized *BRAF* mutations based on their MAPK pathway activation mechanisms into class-1 (high kinase activity involving codon 600), class-2 (high or intermediate kinase activity involving codons outside 600), and class-3 (impaired BRAF kinase activity) (Yao et al., [@B156]). Melanomas with *BRAF* class-1 (V600 mutations) respond well to current FDA-approved BRAF inhibitors (vemurafenib, dabrafenib, and encorafenib), as well as combined BRAF/MEK inhibitor therapy. On the contrary, melanomas with *BRAF* class-2 mutations (non-V600 mutations) do not respond to first-generation BRAF inhibitors, which are monomer selective, but they could be of benefit to MEK/ERK inhibitors as well as the BRAF inhibitor PLX8394 (Dahlman et al., [@B31]; Bowyer et al., [@B12]; Marconcini et al., [@B94]; Janku et al., [@B66]). These class II mutations can be further subdivided into class IIa within the activation segment (L597 and K601) and IIb within the glycine-rich region (G466 and G469) (Dankner et al., [@B33]). Finally, class III mutations (N581 and D594) have no kinase activity but facilitate RAS binding and CRAF activation (Yao et al., [@B156]).

To date, FDA approved only BRAF/MEK inhibitors alone or in combination in presence of *BRAF* V600 mutations. Three combinations of BRAF/MEK inhibitors (vemurafenib plus cobimetinib, dabrafenib plus trametinib, and encorafenib plus binimetinib) are currently available for *BRAF* V600E/K metastatic melanomas, and one combination (dabrafenib plus trametinib) has been recently approved in the adjuvant, Stage III setting (Long et al., [@B84]; Schvartsman et al., [@B126]).

Assessment of *BRAF* Mutations {#s3}
==============================

Several methods have been developed and are currently used for the detection of *BRAF* mutations, including Sanger sequencing, immunohistochemistry (IHC), pyrosequencing, mutation-specific Polymerase Chain Reaction (PCR) and mutation-specific real-time PCR, digital PCR (dPCR), High-Resolution Melting curve analysis (HRM), Matrix Assisted Laser Desorption Ionization-Time Of Flight Mass Spectrometry (MALDI-TOF MS; Sequenom), and Next-Generation Sequencing (NGS). The sensitivity and specificity of the most commonly used diagnostic methods are reported in [Table 1](#T1){ref-type="table"}.

###### 

Sensitivity and specificity of the most commonly *BRAF* diagnostic techniques.

  **Diagnostic technique**         **Sensitivity%**   **Specificity%**   **LOD%**
  -------------------------------- ------------------ ------------------ ----------
  IHC                              93--97             92--98             \-
  Sanger sequencing                80--93             100                20--25
  Pyrosequencing                   95--100            90--100            5--10
  Real-time PCR based techniques   93--99.5           98--100            0.5--5
  dPCR                             100                95                 0.001
  HRM                              87--99             96--99             5.0
  MALDI-TOF MS                     97.6               100                1--5
  NGS                              98                 100                5

Sanger Sequencing
-----------------

Sanger sequencing has long been considered the reference method for the identification of acquired mutations in tumors. It requires a high percentage of tumor cells within the samples, which is not always possible in routine diagnostic testing. In this context, pathologists play a critical role in the triage of melanoma samples for molecular tests since they must estimate the cellularity of the tumor within the designated region to obtain sufficient material to ensure the correct analytical sensitivity of the test required. For this reason, it may be advisable perform macro-dissection by pathologists before mutation testing when tumor cell percentage is \< 50%. Moreover, the sensitivity of Sanger sequencing for V600E detection is 92.5% (Anderson et al., [@B3]), meaning that, using this technique alone, 7.5% of patients potentially eligible for treatment with BRAF and MEK inhibitors would be missed. In this respect, three papers compared Sanger sequencing with the Cobas 4800 BRAF V600 Mutation Test (Roche Molecular Systems, Inc.), an FDA-approved real-time PCR assay to select patients with metastatic melanoma for treatment with the selective BRAF inhibitor vemurafenib or with cobimetinib plus vemurafenib combination (Lopez-Rios et al., [@B88]; Qu et al., [@B113]; Jurkowska et al., [@B73]). Qu et al. analyzed V600 mutations in 275 melanoma FFPE samples and displayed a higher sensitivity for Sanger sequencing than for Cobas 4800 test. The positive percent agreement and negative percent agreement for Sanger sequencing was 97.7 and 95.3%, respectively (Qu et al., [@B113]). Lopez-Rios et al. compared the Cobas BRAF Mutation Test with Sanger sequencing observing invalid results (DNA not amplified, difficult sequence interpretation, insufficient tumor content or DNA) in 8/116 specimens with Sanger vs. 0/232 with the Cobas BRAF test. The positive percent agreement and negative percent agreement was 97.7% and 95.3% for Sanger sequencing (Lopez-Rios et al., [@B88]). Finally, Jurkowska et al. examined *BRAF* mutations in 236 FFPE cutaneous melanoma lymph node metastases by Sanger sequencing tests and the Cobas® 4800 BRAF V600 Mutation Test. The study reported a very similar mutation detection rate between the two methods (60.9% for Sanger sequencing vs. 61.0% for Cobas 4800). Moreover, the sequencing demonstrated a superiority in the detection of mutations other than V600E but a higher susceptibility to DNA quality compared to Cobas 4800 test (Jurkowska et al., [@B73]). In general, the Limit Of Detection (LOD) of clinical assays by Sanger sequencing is \~20% to 25% mutant alleles. However, a lower percent mutant allele may be rarely detected, depending on the context of the targeted sequences (Pichler et al., [@B110]; Tsiatis et al., [@B145]). For these reasons, Sanger sequencing cannot be considered as a reference test but only as a screening or confirmation test (Spagnolo et al., [@B134]).

Immunohistochemistry
--------------------

To date, IHC with VE1 monoclonal antibody is the only available antibody-based test (Capper et al., [@B18]). This test was found to effectively detect V600E mutations (Colomba et al., [@B23]; Long et al., [@B86]). Recently, Vallée A et al. analyzed *BRAF* mutation in 60 metastatic melanoma tissues with BRAF IHC and Idylla^TM^ BRAF Mutation Assay, a real-time PCR assay. In this study, IHC yielded a final Predictive Positive Value (PPV) of 100% and a Negative Predictive Value (NPV) of 93% calculated with V600E mutated samples only (Vallée et al., [@B148]). In another study, the researchers reported a high concordance between allele-specific TaqMan assay and IHC in *BRAF* V600E detection analyzing 97 melanomas of 44 multiple primary melanoma patients. In particular, they reported a concordance of 88.7% (86/97) among the two techniques (Pellegrini et al., [@B109]). Discordant results were founded in 8/97 (8.2%) samples that showed weak or moderately positive VE1 immunostaining (Pellegrini et al., [@B109]). Several works suggest that we be careful in the case of presence of unclear weak staining with VE1 antibody (Busam et al., [@B15]; Ihle et al., [@B64]; Uguen et al., [@B146]). Moreover, Ihle et al. analyzed *BRAF* mutational status in 63 melanoma patients by HRM, pyrosequencing, allele specific PCR, NGS, and IHC reporting a cross-reactivity with no-V600E mutations (Ihle et al., [@B64]).

To perform this highly sensitive and specific test, only two tissue slides are required, and there is no need of specialized equipment. Other advantages of this technique are low costs and time, as results are obtained within 48 h. However, IHC has limitations derived from pre-analytical factors such as heterogeneously stained tumors, low tumor purity, necrotic tumor areas, and a suboptimal fixation condition (Capper et al., [@B18]; Dvorak et al., [@B40]; Fisher et al., [@B42]; Rapisuwon et al., [@B115]). In addition, staining interpretation is not always easy being subject to interpretation by the pathologist (Fisher et al., [@B42]). Moreover, the VE1 antibody is highly specific only for *BRAF* V600E, then IHC may be used as a cost-effective first-line method for *BRAF* V600E as part of a routine combination of methods (Colomba et al., [@B23]; Pearlstein et al., [@B107]; Spagnolo et al., [@B134]; Tetzlaff et al., [@B142]).

Pyrosequencing
--------------

Pyrosequencing differs from Sanger methods for the detection of pyrophosphate release and the generation of light on nucleotide incorporation and not of chain termination with dideoxynucleotides. Pyrosequencing is commonly used to detect *BRAF* mutations and commercial kits are actually available for *BRAF* analysis on this platform, such as therascreen BRAF Pyro kit (Qiagen, Hilden, Germany) (Tan et al., [@B139]). In general, pyrosequencing is unable to accurately detect variants within \>5 or 6 bp homopolymer and can be generate confusing patterns difficult to resolve without further investigation in the case of complex mutations. Moreover, pyrosequencing allows the analysis of single nucleotide polymorphisms or hotspot mutations in a single run since the length of sequence is usually \<200 bp. However, compared with Sanger sequencing, pyrosequencing is a quantitative method, has a superior LOD (5% minor allele frequency), and is faster (Spittle et al., [@B135]). Compared to direct sequencing, pyrosequencing is a rapid and more sensitive method for quantifying the *BRAF* V600 mutations. Across different studies, pyrosequencing sensitivity and specificity for the detection of *BRAF* V600 mutations range from 90 to 100% and from 95 to 100%, respectively (Colomba et al., [@B23]; Ihle et al., [@B64]). Therefore, this technique may be used in those cases in which results provided by IHC and Sanger sequencing are uncertain (Spagnolo et al., [@B134]).

Real-Time PCR-Based Techniques
------------------------------

Real-time PCR-based tests showed a higher sensitivity than Sanger sequencing, with specificity ranging from 88 to 100% depending on whether their design is specific for the V600 mutations. The FDA/CE-IVD-approved tests for *BRAF* mutations (Cobas® 4800 BRAF p.V600 mutation test and THxID®-BRAF) are both real-time PCR-based assays (<http://www.fda.gov/companiondiagnostics>). The main limitation of these approaches is that they are optimized for the most common *BRAF* mutations. In particular, THxID-BRAF kit was approved for the detection of V600E and K mutations and is validated for DNA input ranging from 10 to 350 ng/μl (bioMérieux Corporate Website[^4^](#fn0004){ref-type="fn"}). On the contrary, the Cobas 4800 test is FDA approved only for V600E and has an analytical sensitivity of 95% for detecting the V600E mutation with a recommended DNA input of 125 ng total (125 ng/25 μl for the detection of *BRAF* V600E mutation at ≥ 5%) (Drugs\@FDA: FDA-Approved Drugs[^5^](#fn0005){ref-type="fn"}). In contrast to the Cobas 4800 test, the THxID test has a high degree of sensitivity for both V600E and V600K. In fact, the Cobas® test was found to detect only 70% of V600K (Anderson et al., [@B3]). Recently, CE-IVD real-time PCR tests have been developed to detect all *BRAF* V600 mutations with a sensitivity similar or superior to that observed with pyrosequencing. This is the case of Peptide Nucleic Acid (PNA)-mediated PCR clamping, a real-time PCR method which uses PNAs to bind normal DNA sequences, so that only mutant DNA is amplified. Due to its high sensitivity and specificity (99.5 and 100%), PNA-mediated PCR clamping offers a valid alternative to pyrosequencing (Jeong et al., [@B68]; Bruno et al., [@B13]). Indeed, PNA clamp real-time PCR detected a 0.5% *BRAF* V600E mutant in the background of the WT with high sensitivity since it is based on the principle that PNA inhibits WT by hybridizing normal sequences, and therefore mutant DNA is preferentially amplified.

Another PCR-based technology is the dPCR that is a cost-effective, sensitive method for detecting mutated DNA in tissue or blood samples. dPCR, in its different formats (chamber dPCR and droplet dPCR), differs to quantitative real-time PCR, since DNA mutants can be quantified here without the need for calibration curves (Day et al., [@B35]). A drawback of this technology is that it is able to detect single mutations or sets of highly related mutations at the same locus. Malicherova B et al. compared the sensitivity of four *BRAF* V600E detection methods \[Cobas® 4800 system based on real-time PCR amplification, Sanger sequencing, allele-specific PCR (AS-PCR), and droplet digital PCR (ddPCR) in FFPE melanoma biopsies from 87 consecutive melanoma patients (stage I-V disease)\]. The results indicated good agreement among all four methods about the presence of the *BRAF* V600E mutation reaching a concordance between Cobas® 4800 and ddPCR of 88.9% for *BRAF* and 100% for WT patients. In addition, ddPCR was able to detect the *BRAF* V600E mutation in eight patients that would not have been identified by the others techniques thanks to its detection limit of 0.001% (Malicherova et al., [@B91]). Similarly, in another recent work, researchers compared ddPCR with Sanger sequencing and pyrosequencing in 40 melanoma FFPE tissues regarding the detection rates of mutations in *BRAF, NRAS*, and *TERT* promoter. The study revealed the ddPCR as the most sensitive method, followed by pyrosequencing and then Sanger sequencing. Concordance between the platforms was high in tumors with high neoplastic cell content, whereas, at low tumor cellularity, the sensitivity offered by ddPCR allowed for the detection of mutations at low frequency abundance (McEvoy et al., [@B97]). In addition, Lamy PJ et al. analyzed *BRAF* V600E mutation in 47 metastatic melanoma biopsies by dPCR reaching a LOD of 0.0195% mutated allele. The four assessed methods in this study showed a good concordance, especially when samples with high tumor cellularity are analyzed. In particular, *BRAF* V600E mutation was detected in 22 samples (46.8%) by dPCR, in 21 samples (44.7%) by allele-specific amplification, and in 19 samples (40.4%) samples by HRM and pyrosequencing (Lamy et al., [@B79]). Finally, Bisschop C et al. analyzed 39 FFPE melanoma tissue samples collected by IHC using the anti-BRAF-V600E (VE1) mouse monocolonal antibody (BRAF-VE1 IHC), a V600E-specific ddPCR Test, and the Idylla BRAF- Mutation Test (Idylla). In this study, ddPCR showing a sensitivity of 100% and a specificity of 95% for *BRAF* V600E (Bisschop et al., [@B10]). Based on these results, ddPCR should be the primary method of detecting and monitoring *BRAF* V600E-mutated cutaneous melanomas as methods of screening thanks to the higher sensitivity and lower LOD of mutant allele. Moreover, the higher sensitivity of this method could allow investigating tumor cell mutation heterogeneity and its changes during tumor progression in a more thorough way than with the other methods.

HRM Analysis
------------

HRM analysis is a PCR-based method for the identification of *BRAF* mutations. HRM of nucleic acids depends on the ability to record and evaluate fluorescence intensities as a function of the melting temperature of PCR products. The distinctive melting curve can be used to detect DNA sequence variations in the amplicon without the need for any post-PCR processing. The method is easy to use, highly sensitive, specific, low in cost, and yields rapid sample turn-around. Indeed, HRM compared to other methods is an in-tube method in which the analysis is performed immediately after the amplification and is thus particularly suitable to give a quick response to oncologists on *BRAF* mutation status. Moreover, HRM analysis has an detection limit around 5.0% mutated alleles (Carbonell et al., [@B19]; Ney et al., [@B102]). Franczak C et al. assessed and compared *BRAF* mutations in 59 FFPE melanoma samples using HRM PCR, real-time Allele-Specific Amplification (RT-ASA) PCR, NGS, IHC, and the diagnostics platform Idylla^TM^. Sensitivity and specificity for HRM were 87.1 and 96.4%, respectively and was the less accurate assay for the detection of *BRAF* mutation on exon 15 (Harlé et al., [@B58]; Franczak et al., [@B46]). Marchant J et al. compared the THxID™-BRAF diagnostic test with HRM and Sanger sequencing in 113 melanoma FFPE samples. Although HRM have a relative high sensitivity for mutation detection, it failed to detect three patients with V600 mutation (Marchant et al., [@B93]). In contrast, Ihle et al. showed no difference in sensitivity between the HRM analysis and Sanger sequencing (98%). All mutations down to 6.6% allele frequency could be detected with 100% specificity (Ihle et al., [@B64]). In 2014, a meta-analysis of 14 studies involving 1,324 samples in the detecting *BRAF* mutation indicated that the overall values of the sensitivity and specificity of HRM were 0.99 and 0.99, respectively (Chen et al., [@B22]). Richter et al. carried out a blinded study to evaluate various *BRAF* mutation testing methodologies in FFPE melanoma samples using Sanger sequencing, single-strand conformation analysis (SSCA), HRM and Competitive Allele-Specific TaqMan® PCR (CAST-PCR). Concordance of 100% was observed between the Sanger sequencing, SSCA and HRM techniques (Richter et al., [@B118]). In general, the real-time PCR-based methods achieved a lower LOD than Sanger sequencing, pyrosequencing and HRM analysis (it may detect \<1% of mutated DNA).

MALDI-TOF MS {#s4}
============

MALDI-TOF MS allows multiplexed genotyping and is as a sensitive, reliable, fast, and cost-effective method. The general principle of MALDI-TOF MS is based on amplification of the DNA by PCR, resulting in copies of both mutant and wildtype alleles. Then, primer extension performed using terminator nucleotides A, C, T, and G, each with distinct masses leads to different masses of the amplicons depending on the mutational status that can subsequently be detected by mass spectrometry. Different platforms have been developed by several companies for the simultaneously analysis of various mutations by mass spectrometry, such as MassARRAY® Dx 4 system (Agena Bioscience Inc., San Diego, CA) and Sequenom MassARRAY (Sequenom, San Diego, CA). MassARRAY® system is a non-fluorescent detection platform utilizing mass spectrometry to accurately measure PCR-derived amplicons providing accurate, rapid, and cost-effective analysis (Agena Bioscience Inc., San Diego, CA) with a high level of accuracy and reproducibility. In this context, several commercial panel for somatic mutation profiling using MALDI-TOF MS platforms are available. The iPLEX HS Melanoma panel (Agena Bioscience Inc., San Diego, CA) detects 97 clinically relevant variants in 11 melanoma relevant genes, including *BRAF*, at as low as 1% minor allele frequency from FFPE tissue. Interestingly, Greaves WO et al. compared the sensitivity of MALDI-TOF custom assay (Sequenom MassARRAY; Sequenom, San Diego, CA) with pyrosequencing in the detection of *BRAF* mutations in 145 specimens, including melanomas, finding a concordance between both assays of 99.3% (144/145). Using pyrosequencing as the gold standard, the sensitivity and specificity of the MALDI-TOF assay were 97.6% and 100%, respectively (Greaves et al., [@B57]). In conclusion, MALDI-TOF MS is a robust approach for the genotyping of known mutations with high sensitivity and specificity reaching a LOD of 1--5% of mutant DNA. Moreover, it is versatile, thanks the capability to create custom assays, and have the advantages to multiplexing, such as NGS. However, it has drawbacks such as expensive instruments consumables and with an elaborate post-PCR processing technique.

NGS {#s5}
===

NGS provides far more genetic information: besides single point mutations, NGS allows detection of additional variant types and simultaneous analysis of multiple genes. The importance of multi-gene analysis in melanoma is expected to increase, as more pharmacologically actionable oncogenic mutations will be discovered, and additional targeted treatments become available. NGS techniques are more sensitive than many real-time PCR assays even when tumor DNA represents \<10% of the total DNA. In a study comparing different methods, NGS had 100% specificity and 99% sensitivity, and could be used to study all samples, including those with limited tumor tissue (Ihle et al., [@B64]). Recently, 21 melanoma samples were analyzed with Ion AmpliSeq™ Cancer Hotspot Panel v2 in order to compare NGS performance with the Sequenom MassARRAY system, Sanger sequencing, and allele-specific real-time PCR. NGS identified two correctly mutation at very low frequency in the *BRAF* gene missed both by mass-spectrometry and Sanger sequencing, confirming the high sensitivity of NGS method (LOD of 5%) (Mancini et al., [@B92]). On the other hand, NGS demands expertise in data analysis and its application in a clinical context requires an established workflow to obtain reliable sequencing results. Moreover, it requires more time and is more expensive than most of the other techniques. Since there is no targeted drug available for most alterations that can be detected with NGS, a comprehensive screening of multiple genes by NGS nowadays is considered as a research tool more than a technique to be used in everyday practice. However, limiting the analysis to currently actionable genes (i.e. *BRAF, NRAS*, and *KIT*) in one single experiment seems cost and time effective in the diagnostic setting. Unlike the other methods, it also shows the advantage of a quantitative detection of variant allele frequency. In addition to the NGS panels offered through service, the laboratories use commercial panels approved CE-IVD (when available), commercial panels formally aimed only for research use and panel developed by clinical researchers (laboratory developed techniques, LDT). Based on current guidelines, the use of panels no CE-IVD for the diagnostic is allowed where it concerns validated tests for which an internal and external quality assessment laboratory verification phase has been carried out. For the external quality assessment, the European Molecular Genetics Quality Network (EMQN) provide several schemes, such as melanoma scheme to evaluate the capability to assess genotyping and clinical interpretation of *BRAF* gene mutations and NEXTGEN (S) for assessment of genotyping and quality of somatic NGS raw data (<http://www.emqn.org/emqn/Home>). The implementation of an NGS test in a diagnostic laboratory is an extremely complex process that must be documented in a timely manner. Validation of a new diagnostic test involves definition of the performance specifications that it must meet and the demonstration that its performance has been achieved in terms of accuracy, limits and accuracy of the results (Jennings et al., [@B67]). For this purpose, diagnostic specimens or commercially available reference standard controls containing the same mutations of interest should be used for validation. It is also imperative to include a broad spectrum of allele frequencies of the variants investigated to establish the detection limits for the various types of mutation. Moreover, the validation must identify the limitations of the technique including the amount of DNA needed and the minimal tumor cells content in order to guarantee adequate analysis result. For molecular laboratories without these capacities, the use of pre-tested and validated panels available on the market may be the best option, given the complexity of validating an LDT test. However, even if commercial panels are used, both IVD and research, it is essential that the laboratory validated it before its implementation in clinical diagnostics. Actually, several companies developed CE-IVD NGS panels, but, to date, only Sentosa SQ Melanoma Panel (Vela Diagnostics) is specific for melanoma; it is able to detect 127 hot spot mutations and sequence variants in 10 melanoma genes with a mutation detection sensitivity of 5%. Moreover, the only melanoma NGS panel approved by the FDA is the FoundationOne CDx™ (F1CDx™) that it is able to detect substitutions, insertion and deletion alterations (indels), and Copy Number Alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures, including microsatellite instability and TMB using DNA isolated from FFPE tumor tissue. However, the application of FoundationOne CDx™ is not recommended in routinely cutaneous melanoma diagnostic test. In summary, in order to perform the full characterization required in advanced cutaneous melanoma diagnostic setting, the employment of NGS panel resulted faster and required less DNA compared to other diagnostic methods that analyze single mutation or region. These aspects are fundamental in terms of working days and to spare sample for confirmatory tests. Currently, NGS is already used in clinical practice in several centers (Reiman et al., [@B117]; Mancini et al., [@B92]; Park et al., [@B105]). In the future, it is expected that NGS will be routine in molecular diagnostics, in view of the high sensitivity and multiplexing options that allow the molecular profiling of each tumor sample (Spagnolo et al., [@B134]). In a study performed on 100 primary melanomas matched with 25 metastatic tumors aimed to identify the best combination of methods for detecting *BRAF* mutations (among PNA-clamping real-time PCR, IHC, and Sanger sequencing), a *BRAF* mutation frequency of 62%, based on the combination of at least two techniques was obtained (Bruno et al., [@B13]). Concordance between mutation status in primary and metastatic tumor was good but not complete (67%), when agreement of at least two techniques were considered. NGS was used to quantify the threshold of detected mutant alleles in discordant samples. Combining different methods excludes that the observed heterogeneity is technique-based. Therefore, an algorithm for *BRAF* mutation testing based on agreement between IHC and PNA was proposed; a third molecular method could be added in case of discordance of the results. Testing the primary tumor when the metastatic sample is unavailable is a good option if at least two methods of detection are used; however, the presence of intertumoral heterogeneity or the occurrence of additional primaries should be carefully considered (Bruno et al., [@B13]).

Diagnostic Algorithm
--------------------

Overall, in the daily diagnostics and clinical practice, a sequential analysis of two methods, with initial detection of V600E-positive cases by IHC together with a molecular mutation testing technique, such as Sanger sequencing, followed by pyrosequencing or real-time PCR-based, or NGS, can be suggested. In fact, the use of IHC alone carries a significant risk of false negative results and should not be considered unless the sample DNA yield is no sufficient for molecular analysis. On the other hand, a positive result from a sensitive molecular technique may reflect a minor *BRAF*-mutated subclone in a predominantly wild-type tumor, and this is thus not clinically relevant in terms of response to targeted therapy. As described above, an NGS approach to the detection of *BRAF, NRAS*, and *KIT* mutations in one single step can be considered in clinical practice, with the advantage of high sensitivity and quantitative information in terms of variant allele frequency and a lower cost compared to the single analysis of the three genes.

Emerging Techniques: Liquid Biopsy {#s6}
==================================

Liquid biopsy is a non-invasive diagnostic technique for the evaluation of tumor genetic status based on the analysis of circulating free DNA (cfDNA) from different body fluids, such as plasma and serum. Since blood samples are easily obtainable, plasma or serum biopsy has long been considered as a promising non-invasive method to be integrated into traditional biopsy techniques for molecular analysis. One way in which tumors provide information in the form of biomarkers, such as circulating tumor DNA (ctDNA), is through tumor cell necrosis with subsequent release of dead cells or cellular debris. Afterwards, phagocytes incorporate these cells processing and then release the ctDNA in blood in the form of small fragments. ctDNA is the cfDNA that is shed from tumor cells, and it can be analyzed for the same genetic alterations found in the tumor (Lipson et al., [@B82]; Knol et al., [@B75]; Gangadhar et al., [@B51]; Long-Mira et al., [@B87]). In addition to ctDNA, Circulating tumor Cells (CTCs) or exosomes can provide tumor DNA for liquid biopsy. Besides ctDNA, CTCs are intact tumor cells released into the bloodstream that can be used as a source to extract tumor DNA (Zhang et al., [@B157]). Finally, exosomes are extracellular membrane vesicles, with a size between 40 and 100nm, that are released by most cells, including cancer cells, and they therefore can be used in liquid biopsy as a source of DNA, RNA, and tumor proteins (Vanni et al., [@B151]; [Figure 2](#F2){ref-type="fig"}).

![Liquid biopsy as surrogate biomarker in melanoma. Abbreviations: cfDNA, cell free DNA; ctDNA, circulating tumor DNA; CTCs, circulating tumor cells.](fmolb-07-00113-g0002){#F2}

cfDNA/ctDNA
-----------

cfDNA in blood was first discovered in 1948 and has emerged as a promising diagnostic tool for cancer patients (Diaz and Bardelli, [@B37]). The total amount of cfDNA in the plasma and serum of cancer patients varies from patient to patient but cancer patients have higher plasma and serum cfDNA levels than patients without cancer (Leon et al., [@B81]; Fournié et al., [@B45]). Indeed, cfDNA concentration in blood varies significantly; it ranges between 0--5 and \>1000 ng/ml in patients with cancer and between 0 and 100 ng/ml in healthy subjects (Schwarzenbach et al., [@B127]). In general, several studies have shown that cfDNA is present in small quantities also in the blood of healthy individuals and increases in patients suffering from a series of clinical disorders such as cancer, stroke, trauma, myocardial infarction, autoimmune diseases, and complications associated with pregnancy (Swarup and Moganty, [@B138]). In melanoma cancer patients, plasma cfDNA levels are higher in advanced patients with a median of 135 pg/μl ranging from 17 pg/μl to 1.125 pg/ml of plasma compared to early stage (Valpione et al., [@B149]). There are several hypotheses regarding the release of cfDNA in the circulatory stream, but the one most accepted by the scientific community consists in the necrosis and apoptosis of the tumor cells or through their active release (Stroun et al., [@B137]). According to this hypothesis, apoptotic and necrotic cancer cells and DNA strands, which are not phagocytized, enter in the bloodstream as cfDNA (Jahr et al., [@B65]). The estimated size of cfDNA varies from \~40--200 bp, with a peak at about 166 bp, which are characteristic of the apoptotic process (Snyder et al., [@B132]; Zhang et al., [@B158]; Mouliere et al., [@B101]). However, individual cfDNAs might carry thousands of base pairs (\>20--30 kb) as result from necrotic cell death (Thierry et al., [@B143]). In the cancer context, liquid biopsy in metastatic melanoma has emerged as a complementary tool to tumor biopsies for detection of actionable alterations. Indeed, it enables non-invasive and quantitative characterization of the whole tumor genome, identification of tumor heterogeneity, and clonal evolution during treatment and toward disease progression in cancer patients, including melanoma (Ascierto et al., [@B4]; Bettegowda et al., [@B9]; Lebofsky et al., [@B80]; Sanmamed et al., [@B123]; Santiago-Walker et al., [@B124]). As it is known, a requirement for administration of BRAFi/MEKi is the identification of a *BRAF* mutation in specific melanoma samples, which, however, may not represent the current somatic mutation status or tumor heterogeneity. ctDNA analysis allowing for real-time comprehensive mutation assessment of all tumor sites within a patient may overcome this limitation. Beyond that, the minimally invasive nature of ctDNA sample acquisition enables routine monitoring of response and resistance to targeted therapy. Nevertheless, the disadvantages of using ctDNA for molecular investigations are the follows: (i) very low ctDNA concentrations that are often not sufficient to carry out molecular investigations; (ii) ctDNA which represents between 0.01 and 10% of the total cfDNA and therefore the need for highly sensitive technologies for the evaluation of the presence of genetic alterations of interest; and (iii) the very fragmented nature of the ctDNA, which requires tests for the detection of genetic alterations of interest suitable for the analysis of portions of DNA of about 100--200 bp.

Chiefly, its highly fragmented nature (Diehl et al., [@B38], [@B39]; Fleischhacker et al., [@B44]) and the minor fraction of ctDNA with a variable contribution of 0.01 to 10% of total cfDNA (Diehl et al., [@B38]; Dawson et al., [@B34]) are of high importance with respect to the desired sensitivity of the selected detection method and the preanalytical sample handling. Indeed, the most common mistakes include the selection of the use of inappropriate blood collection tube (e.g., hemolysis or insufficient volume), wrong sample storage and transportation, and inappropriate DNA extraction and mutation detection tests. However, to date there are no integrated, multicenter-tested workflows available covering the requirements for the use of liquid biopsy in the clinical setting. Indeed, currently there is only one FDA-approved ctDNA based mutation test but only for the detection of *EGFR* mutations in NSCLC patients: the Cobas EGFR Mutation Test v2 (Cobas EGFR Mutation Test v2. 2016. Available online at: <http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm504540.htm>).

Although many different liquid biopsy technologies have been recently developed, there is still a lack of established workflows from the sample to clinically meaningful data. In addition, many standard molecular biology techniques for the detection of potentially targeting melanoma mutations are not suitable for the analysis of ctDNA due to their low sensitivity. In fact, since ctDNA often represents a small percentage of the total cfDNA, somatic mutations from the tumor can be present in extremely low allele fractions (up to 0.01%). For this reason, highly sensitive methodologies or modifications of pre-existing technologies have been developed in order to detect low-frequency mutations in cfDNA of melanoma patients, such as Allele-specific amplification Refractory Mutation System PCR (ARMS), Bead Emulsification Amplification and Magnetics (BEAMing) technology, Allele-Specific PCR (AS-PCR), PNA-PCR clamping technique, ddPCR, and NGS (Crowley et al., [@B28]; Volik et al., [@B152]; Busser et al., [@B16]; [Table 2](#T2){ref-type="table"}). However, in metastatic melanoma, there is usually enough tumor tissue available for genetic analyses. Therefore, the mutation testing in the liquid biopsy of melanoma patients is not to be a surrogate of solid biopsy and it should only be limited in case there is not enough material or in order to offer additional clinically relevant information, such as clonality and tumor heterogeneity. It is notable that the liquid biopsy, and in particular cfDNA and CTCs, are not only important for the detection of clinically relevant mutations in melanoma but also for its prognostic and predictive value for patient outcome and response to therapy (Busser et al., [@B16]; Gaiser et al., [@B50]).

###### 

Overview of techniques used for the detection of *BRAF* mutation in cfDNA from melanoma patients.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Method**                                               **Gene**\                              **Sensitivity**\            **References**
                                                           **(mutation)**                         **(% of mutated copies)**   
  -------------------------------------------------------- -------------------------------------- --------------------------- -----------------------------------
  ddPCR                                                    BRAF V600E                             0.001%                      Burjanivova et al., [@B14]

  ddPCR                                                    TERT promoter                          0.031--0.063%               Corless et al., [@B25]

  ddPCR                                                    BRAF V600E                             0.001%                      Malicherova et al., [@B91].

  ddPCR                                                    BRAF V600E                                                         Tang et al., [@B140]

  ddPCR                                                    TERT promoter                          0.17%                       McEvoy et al., [@B96]

  ddPCR                                                    BRAF V600E,\                           0.1%                        Gray et al., [@B55]
                                                           BRAF V600K,\                                                       
                                                           NRAS Q81K,\                                                        
                                                           NRAS Q61R                                                          

  ddPCR                                                    BRAF V600E,\                           0.01                        Chang-Hao Tsao et al., [@B21]
                                                           BRAF V600K,\                                                       
                                                           NRAS Q81K                                                          

  ddPCR                                                    BRAF V600E                             0.001                       Sanmamed et al., [@B123]

  MassArray System                                         13 genes                                                           Gray et al., [@B56]

  BEAMing technology                                       BRAF V600E,\                           0.01%                       Santiago-Walker et al., [@B124]
                                                           BRAF V600K                                                         

  BEAMing technology                                       BRAF V600E,\                           \<0.01                      Lipson et al., [@B82]
                                                           NRAS Q81K,\                                                        
                                                           NRAS Q61R                                                          

  BEAMing technology                                       BRAF V600E,\                           0.01                        (Ascierto et al., [@B4]; 2118436)
                                                           BRAF V600K                                                         

  BEAMing technology                                       BRAF V600E,\                           0.03%                       Rowe et al., [@B120]
                                                           BRAF V600K, NRAS Q61K, NRAS Q61R,\                                 
                                                           NRAS Q61L,\                                                        
                                                           NRAS Q61H                                                          

  Quantitative real-time clamp reverse transcription PCR   BRAF V600E                             0.001                       Shinozaki et al., [@B129]

  CastPCR                                                  BRAF V600E                             0.5                         Ashida et al., [@B5]

  AS-real-time PCR                                         BRAF V600E                             0.3%                        Pinzani et al., [@B111]

  AS-PCR or ARMS                                           BRAF V600E,\                           0.1%                        Board et al., [@B11]
                                                           BRAF V600K,\                                                       
                                                           BRAF V600D                                                         

  AS-PCR or ARMS                                           BRAF V600E                             0.3%                        Cao et al., [@B17]

  AS-PCR or ARMS                                           BRAF V600E                             0.25%                       Daniotti et al., [@B32]

  AS-PCR or ARMS                                           BRAF V600E                             2%                          Aung et al., [@B6]

  ARMS                                                     BRAF V600E,\                           1.82--4.85%                 Knol et al., [@B75]
                                                           BRAF V600K,\                                                       
                                                           BRAF V600R,\                                                       
                                                           BRAF V600D                                                         

  AS-PCR                                                   BRAF V600E,\                           0.01%                       Schreuer et al., [@B125]
                                                           BRAF V600K,\                                                       
                                                           BRAF V600R,\                                                       
                                                           BRAF V600D                                                         

  Mutant-specific PCR                                      BRAF V600E                             0.01%                       Yancovitz et al., [@B155]

  Real-time PCR + restriction enzyme digestion             BRAF V600E                             0.1%                        Panka et al., [@B104]

  Biochip assay (Nested LNA-Clamp PCR)                     BRAF V600E, BRAF V600M, BRAF V600K,\                               Emelyanova et al., [@B41]
                                                           BRAF V600R, BRAF V600D                                             

  NGS                                                      Exome                                                              Girotti et al., [@B53]

  NGS                                                      Whole genome                                                       Cutts et al., [@B30]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------

CTCs and Exosomes
-----------------

The CTCs evaluation for the identification of melanoma actionable mutations is limited compared to ctDNA assessment since the use of either CTCs marker or size-based enrichment methods leads to the loss of surface marker negative or small CTCs, respectively. Moreover, the typically only 1--10 CTCs can be found in 4 ml of blood of metastatic melanoma patients, and, for this reason, CTC enrichment methods and a highly sensitivity method are mandatory in order to identify melanoma mutations (Freeman et al., [@B47]). To date, therefore, the clinical utility of melanoma CTCs is still unclear due to rarity and heterogeneity and a lack of a standardized isolation. Sakaizawa K et al. have analyzed CTC isolated from blood of 11 melanoma patients using immunomagnetic beads coated with HMW-MAA-specific antibodies followed by immunohistochemical laser dissection techniques in order to genotypes *BRAF* and *KIT* genes by PCR amplifications. This study highlighted that the genotypes of the CTC differed from those of the primary tumors, and the metastatic lesions suggest clonal heterogeneity. The success rate of PCR amplification for *BRAF* evaluation and *KIT* from single CTC ranged from 20 to 100% and from 0 to 50%, respectively (Sakaizawa et al., [@B122]). In a more recent study, researchers used immunomagnetic beads for CTCs enrichment from metastatic melanoma patients blood with BRAF mutated tumors (Reid et al., [@B116]). The DNA extracted from CTCs has been subjected to Wool Genome Amplification (WGA) and tested for *BRAF* V600E or V600K mutations by ddPCRs. The study demonstrated that WGA combined with ddPCR allows the detection of cancer mutations in CTCs after partial isolation by enrichment since *BRAF* V600E mutations was found in all patients at a fractional abundance ≥ 0.0005% (Reid et al., [@B116]).

Kiniwa Y et al. used a high-density dielectrophoretic microwell array following by single-cell sequencing in 33 CTCs to reveal *BRAF* status from a patient with advanced melanoma revealing an heterogeneous *BRAF* status in CTCs (Kiniwa et al., [@B74]). On the other hand, Hofman V et al. has combined ISET and IHC using the VE1 antibody to investigate the presence of *BRAF* V600E in CTC isolated in 87/98 (89%) melanoma patients. In particular, of 87 patients, 54 (62%) demonstrated positive immunostaining on ISET filters, and, among 46 (85%) patients with *BRAF* mutation, the V600E mutation was also identified in tissue specimen by pyrosequencing. In contrast, 8/54 (15%) patients with positive VE1-immunostained CTCs lacked *BRAF* V600E in tumor tissues (Hofman et al., [@B62]).

Finally, very few studies have been carried out on the *BRAF* mutation status in DNA inside exosomes in melanoma (García-Silva et al., [@B52]). It is well-known that exosomes, besides their specific surface proteins, also carry a select set of functional circulating nucleic acids such as mRNAs, miRNAs, LncRNAs, and DNA (Schwarzenbach et al., [@B127]). Very recently, Garcia et al. found that the *BRAF* V600E mutation can be detected in exudative seroma (ES)-derived extracellular vesicles by quantitative PCR (LOD of 0.01%) and also correlated with risk of relapse. The researchers pointed out as the detection of *BRAF* mutation in ES vesicles obtained through lymphatic drainage may be a novel parameter to identify melanoma patients at risk of relapse probably due to the presence of residual disease (García-Silva et al., [@B52]).

In conclusion, despite the high potential of liquid biopsy, its systematic application in real practice is still limited, especially in the detections of relevant mutations, due to many hindrances, such as unsatisfactory specificity and sensitivity, lack of standardization, and elevated economic and human resource costs; it thus still offers many challenges. Last but not least, the onset of drug resistance mechanisms could be identified in melanoma patients using the liquid biopsy ([Figure 2](#F2){ref-type="fig"}).

Conclusion and Perspectives {#s7}
===========================

In summary, with the introduction of effective targeted therapy for the treatment of *BRAF*-mutant melanoma, which account for about 50% of all melanomas, it is now mandatory to assess the molecular status of all stage IV patients and, in light of the approval of BRAF and MEK inhibitors in the adjuvant setting, of patients with high-risk, resected stage III melanoma. Therefore, molecular testing for *BRAF* mutations is a priority in determining the course of therapy. In this view, several different techniques for *BRAF* testing are currently developed and used by various laboratories. The choice of methods employed by the center should take into account the specific sensitivity, reproducibility, accuracy, running time, and analysis cost of the assay. Moreover, the choice and use of techniques able to quantify the mutant allele frequency of *BRAF* gene is important since it is reported to influence the clinical efficacy of the BRAF/MEK inhibitors treatments. So, quantitative analysis of the *BRAF* gene could be useful to select the melanoma patients who are most likely to benefit from target therapy (Stagni et al., [@B136]). In addition, intertumoral and intratumoral heterogeneity could lead to misinterpretation of *BRAF* mutational status; this is especially important if testing is performed on primary specimens, or micromestasis, when abundant metastatic lesions are unavailable. In this context, the characterization of molecular heterogeneity in advanced melanoma patients could be overcome by the analysis of liquid biopsy that represent an efficient non-invasive tool to overcome the problem. Potential of circulating biomarkers in liquid biopsy diagnostics holds promise as a tool for diagnosis and treatment of melanoma, including early diagnosis screening, tumor heterogeneity, drug resistance, and establishment of targets. Several efforts are being made to standardize extraction and molecular analysis technologies and protocols in order to implement the liquid biopsy assays in cancer field hoping it could be replacing tissue biopsy in the near future. In fact, the need to obtain recurrent molecular assessments will become increasingly greater in order to offer the most suitable therapy for the patient from time to time. Moreover, liquid biopsy may be more representative of patient\'s whole disease than an isolated portion of tumor tissue, and this is particularly important due to tumor heterogeneity. The opportunity to obtain these assessments without recurring to invasive procedures and, above all, being able to evaluate patients with surgically inaccessible lesions will be a milestone in the treatment of melanoma.
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